J&J's Alios BioPharma Reports Presented Positive Results of Anti-RSV Nucleoside Analog AL-8176

Loading...
Loading...
Alios BioPharma, Inc. presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus (RSV). AL-8176 achieved its primary and secondary endpoints of reduction in viral load (p < 0.0002) and improvement in symptom scores (p < 0.05) as compared to placebo. AL-8176 was wel l tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge (Day 12), all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. The Alios study enrolled 62 healthy adult volunteers between the ages of 18 - 45 who received one of three dose regimens of AL-8176 or placebo over 5 days: 375 mg orally administered twice daily or 750 mg given as a single loading dose (LD) followed by twice daily maintenance doses (MD) of 150 mg or 500 mg. Administration of AL-8176 or placebo was initiated 12 hours after confirmation of RSV infection as determined by presence of RSV RNA in nasopharyngeal washes. Thirty-five of the 62 pat ients met the criterion for infection (ITT-I population). The data was presented by John DeVincenzo, MD, Professor of Pediatrics and Professor of Microbiology, Immunology and Biochemistry at the University of Tennessee School of Medicine, as part of a late-breaker session on Saturday, October 11 at the IDWeek 2014 meeting. "These positive data represent a validation of the potent antiviral effects of an RSV replication inhibitor and further demonstrate the progress that Alios has made towards developing a therapy for RSV infections, a disease which affects millions of children in the US and untold more worldwide," stated Dr. DeVincenzo. "The ongoing trial assessing the impact of AL-8176 in infants with RSV is an important next step and will be the first opportunity to assess efficacy and safety of AL-8176 directly in those who need it most."
Loading...
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...